Olympion Therapeftirio General Clinic Of Patras S.A.

Patra 17 trials 8 recruiting

17 Registered trials

8 Currently recruiting

Organisation

Olympion Therapeftirio General Clinic Of Patras S.A.

Location

Patra, Greece

Identifier

ORG-100044478

Address

Volou & Meilichou, Kato Sychaina, 264 43, Greece

Departments

Haematology & Oncology Dept.
Hematology
Hematology & Oncology Clinic
Hematology and Oncology Department
Hematology Department
Oncology Clinic
Oncology Department
Pathological Division of Oncology
Pathological Oncology unit
Rheumatology
Rheumatology Department

Clinical trials at this site (17)

Search interface

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Relapsed Refractory Multiple Myeloma 5
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with Immune Thrombocytopenia Recruiting

2024-520359-26-00 Immune Thrombocytopenia (ITP) 4 2025-08-20
A study to investigate the efficacy, safety, and pharmacokinetics of oral rilzabrutinib compared with placebo in participants 18 years of ag… Recruiting

2024-517972-39-00 Autoimmune haemolytic anaemia 5 2025-08-19
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting

2024-514539-67-00 Systemic Sclerosis 4 2025-06-27
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
A study to investigate efficacy, safety, and tolerability of mavorixafor in participants with congenital and acquired primary autoimmune and… Recruiting

2023-508482-32-00 Neutropenias 5 2024-07-22
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi… Recruiting

2023-507396-21-00 transfusion-dependent α- or β-thalassemia or low-risk m 4 2023-03-16
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Treatment of Sjögren’s disease 4 2025-09-17
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously… Ended

2024-512147-23-00 Chronic Lymphocytic Leukemia 10 2024-11-21
HARMONi-3 Ended

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally 5 2023-10-12
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended

2024-510800-35-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-06-17
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended

2023-507890-17-00 Anemia associated with myeloproliferative neoplasm (MPN 5 2021-02-22
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18